Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Earnings

Quantum BioPharma Provides Corporate Update

By The Northwire Desk — AI Analysis Mar 10, 2026 · 19:45 QNTM · 3.99 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma will release its Q4 2025 and full‑year 2025 financial and operational results on March 24, 2026.
  • The company is launching a non‑brokered private placement of up to 4,000 convertible debenture units at $1,000 each, each unit comprising one secured convertible debenture and 250 common share purchase warrants.
  • Proceeds from the offering will be used for ongoing development of its business model and general working capital; the company also plans a related‑party debt settlement by issuing shares to certain creditors.

Key Details

  • Earnings Release: Results for the quarter and year ended December 31, 2025 will be posted after markets close on March 24, 2026 on SEDAR+, EDGAR, and the company website.
  • Private Placement Offering:
  • Up to 4,000 convertible debenture units at $1,000 per unit (C$).
  • Each unit contains:
    • One secured convertible debenture (face value $1,000) bearing interest 1.25 % per month, payable quarterly in cash starting June 30, 2026; maturity 24 months from issuance.
    • 250 common share purchase warrants, each warrant exercisable for one Class B subordinate voting share at $5.00 per share for five years from issuance.
  • Conversion terms: Debenture principal (or portion) and accrued interest may be converted into shares at a conversion price of $4.00 per share.
  • Use of Proceeds: Funding the company’s ongoing business‑model development and general working capital.
  • Debt Settlement:
  • Company will settle amounts owed to arm’s‑length creditors and insiders by issuing shares at the same $4.00 conversion price.
  • Transaction qualifies as a “related party transaction” under MI 61‑101; exemptions from formal valuation and minority‑shareholder approval are being relied upon because the transaction is <25 % of market cap.
  • Regulatory Notices: Securities are not registered in the United States and may not be offered or sold to U.S. persons absent an exemption. All amounts expressed in Canadian dollars.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other